Jacek Bielawski

US Patent:

8592419, Nov 26, 2013

Filed:

Oct 31, 2005

Appl. No.:

11/666519

Inventors:

Alicja Bielawska - Charleston SC, US
Yusuf A. Hannun - Sullivan's Island SC, US
James Norris - Mount Pleasant SC, US
Zdzislaw M. Szulc - Charleston SC, US
Jacek Bielawski - Charleston SC, US
David A. Schwartz - Summerville SC, US
David H. Holman - Charleston SC, US
Ahmed M. El-Zawahry - Charleston SC, US
John McKillop - Charleston SC, US

Assignee:

MUSC Foundation for Research Development - Charleston SC

International Classification:

A61K 31/40
A61K 31/44
A61K 31/415
A61K 31/445
A61K 31/497
A61K 31/535
C07D 211/00
C07D 213/06
C07D 207/00
C07D 233/00
C07D 295/00

US Classification:

5142378, 51425212, 514315, 514357, 514399, 514408, 544162, 544402, 546246, 546251, 5483351, 548400

Abstract:

The invention provides the compounds of formula (): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, A, X, Y, a, b and n are as defined herein. Also disclosed are methods for making the compounds of formula (I) and their use in treating or preventing diseases associated with cell overproliferation and dysfunctional sphingolipid signal transduction. The invention also encompasses the use of the compounds in combination with an apoptosis-signaling ligand, such as Fas ligand. Preferably, the Fas ligand is administered in the form of a gene therapy agent.